Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

Therapeutic Outcomes Wide Association Scan of different antipsychotics in patients with schizophrenia: randomized clinical trials and multi-ancestry validation

Evidence

Psychiatry Clin Neurosci. 2023 May 21. doi: 10.1111/pcn.13567. Online ahead of print.

ABSTRACT

AIM: This study identified discrepant therapeutic outcomes of antipsychotics.

METHODS: A total of 5191 patients with schizophrenia were enrolled, 3030 as discovery cohort, 1395 as validation cohort, and 766 as multi-ancestry validation cohort. Therapeutic Outcomes Wide Association Scan was conducted. Types of antipsychotics (one antipsychotic vs. other antipsychotics) were dependent variables, therapeutic outcomes including efficacy and safety were independent variables.

RESULTS: In discovery cohort, olanzapine related to higher risk of weight gain (AIWG, OR: 2.21 ~ 2.86), liver dysfunction (OR: 1.75 ~ 2.33), sedation (OR: 1.76 ~ 2.86), increased lipid level (OR: 2.04 ~ 2.12), and lower risk of extrapyramidal syndrome (EPS, OR: 0.14 ~ 0.46); risperidone related to higher risk of hyperprolactinemia (OR: 12.45 ~ 20.53); quetiapine related to higher risk of sedation (OR = 1.73), palpitation (OR = 2.87), increased lipid level (OR = 1.69), lower risk of hyperprolactinemia (OR: 0.09 ~ 0.11), and EPS (OR: 0.15 ~ 0.44); aripiprazole related to lower risk of hyperprolactinemia (OR: 0.09 ~ 0.14), AIWG (OR = 0.44), sedation (OR: 0.33 ~ 0.47), and QTc prolongation (β = -2.17); ziprasidone related to higher risk of increased QT interval (β range: 3.11 ~ 3.22), nausea (OR: 3.22 ~ 3.91), lower risk of AIWG (OR: 0.27 ~ 0.46), liver dysfunction (OR: 0.41 ~ 0.38), and increased lipid level (OR: 0.41 ~ 0.55); haloperidol related to higher risk of EPS (OR: 2.64 ~ 6.29), hyperprolactinemia (OR: 5.45 ~ 9.44), and increased salivation (OR: 3.50 ~ 3.68). Perphenazine related to higher risk of EPS (OR: 1.89 ~ 2.54). Higher risk of liver dysfunction in olanzapine and lower risk of hyperprolactinemia in aripiprazole were confirmed in validation cohort, and higher risk of AIWG in olanzapine and hyperprolactinemia in risperidone were confirmed in multi-ancestry validation cohort.

CONCLUSION: Future precision medicine should focus on personalized side-effects. This article is protected by copyright. All rights reserved.

PMID:37210704 | DOI:10.1111/pcn.13567

Document this CPD Copy URL Button

Google

Google Keep

LinkedIn Share Share on Linkedin

Estimated reading time: 5 minute(s)

Latest: Psychiatryai.com #RAISR4D Evidence

Cool Evidence: Engaging Young People and Students in Real-World Evidence

Real-Time Evidence Search [Psychiatry]

AI Research

Therapeutic Outcomes Wide Association Scan of different antipsychotics in patients with schizophrenia: randomized clinical trials and multi-ancestry validation

Copy WordPress Title

🌐 90 Days

Evidence Blueprint

Therapeutic Outcomes Wide Association Scan of different antipsychotics in patients with schizophrenia: randomized clinical trials and multi-ancestry validation

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

More Evidence

Therapeutic Outcomes Wide Association Scan of different antipsychotics in patients with schizophrenia: randomized clinical trials and multi-ancestry validation

🌐 365 Days

Floating Tab
close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI RAISR 4D System Psychiatry + Mental Health